Company intelligence / Profile preview

Alinea Pharmaceuticals

Newton, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

Alinea Pharmaceuticals was a Newton, Massachusetts-based biotechnology company focused on the development of novel therapeutics for metabolic diseases, including type 2 diabetes and obesity. The company specialized in oral delivery technologies for peptides and proteins, aiming to improve patient compliance and therapeutic outcomes for drugs that traditionally require injection. Founded by industry veterans from Altus Pharmaceuticals and Alnylam, Alinea was acquired by AstraZeneca in 2014 to bolster its metabolic disease pipeline. The acquisition integrated Alinea's early-stage programs and delivery expertise into AstraZeneca's MedImmune division.

Therapeutic areas: Endocrinology
Modalities: Peptides
Industry: Biotech

Partnerships

AstraZeneca

Beyond the preview

Go deeper on Alinea Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alinea Pharmaceuticals.

Explore the full profile